Role of phosphoprotein phosphatases in the corpus luteum: II control of progesterone secretion by isolated rat luteal cells.
The key role of protein kinases and protein phosphorylation in the regulation of luteal steroidogenesis is well documented. However the role of phosphoprotein phosphatases (PP) and dephosphorylation in the regulation of luteal cell progesterone secretion is as yet unknown. We have recently demonstrated the presence and activity of PP1 and PP2A in rat luteal cells and the present study was undertaken to determine the consequences of inhibiting PP activity in terms of progesterone secretion. Three structurally dissimilar inhibitors of PP1/2A, okadaic acid, calyculin A and cantharidin each caused a dose-dependent inhibition of LH-induced progesterone secretion without affecting cyclic AMP accumulation. The less potent derivative of okadaic acid, norokadaone, had no effect on either parameter, suggesting that the inhibitory actions on progesterone secretion are due to their specific actions on PP activity and that this inhibition occurs principally at a locus which is distal to the generation of cyclic AMP. In contrast to the inhibitory effects of PP1/2A inhibitors on progesterone biosynthesis, a PP2B inhibitor, cypermethrin, had no effect on LH-stimulated steroidogenesis. The three PP1/2A inhibitors also caused a concentration-dependent inhibition of dibutyryl cyclic AMP-stimulated progesterone secretion. However, none of the inhibitors affected 22R-hydroxycholesterol-supported steroidogenesis, clearly demonstrating that the inhibitors did not interfere with the activity of steroidogenic enzymes. These results suggest that cycles of phosphorylation/dephosphorylation of specific proteins are required for the sustained production of progesterone. Whilst the precise location and function of putative PP substrates is uncertain, the present results indicate that they are involved in regulating the availability of free cholesterol to steroidogenic enzymes within mitochondria.
Abayasekara
D R
DR
Department of Physiology, Royal Free Hospital School of Medicine, London, UK.
Ford
S L
SL
Persaud
S J
SJ
Jones
P M
PM
D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002193:Cantharidin / Q000494:pharmacology; D002478:Cells, Cultured; D003338:Corpus Luteum / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D007986:Luteinizing Hormone / Q000494:pharmacology; D008387:Marine Toxins; D019319:Okadaic Acid / Q000494:pharmacology; D010080:Oxazoles / Q000494:pharmacology; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors / Q000502:physiology*; D010766:Phosphorylation; D011374:Progesterone / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley
D008387:Marine Toxins; D010080:Oxazoles; D019319:Okadaic Acid; D011374:Progesterone; D003994:Bucladesine; C059041:calyculin A; D007986:Luteinizing Hormone; D000242:Cyclic AMP; D010749:Phosphoprotein Phosphatases; D002193:Cantharidin